Thyrocare Technologies Limited
₹457.00-₹58.20 (-11.3%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹7,453 Cr
- P/E
- 62.0x
- EV / EBITDA
- 52.5x
- Revenue
- ₹633 Cr
- Net margin
- 13.5%
- ROCE
- 24.6%
Price chart
Technical chartScreen technicals →+1.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -14.5%
- 3M
- -22.6%
- 6M
- +14.1%
- 1Y
- +1.6%
- 5Y
- +19.0%
52-week range
Day change -₹58.20 (-11.3%) from ₹515 to ₹457 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in THYROCARE, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 134.0%
Concerns0
Rule-based from financial data. Not advice.
About the company
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology.
Read moreShow less
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of testing equipment and consumables; and glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
- Sector
- Technology
- Shares outstanding
- 15.9 Cr shares
- ISIN
- INE594H01019
- BSE code
- 539871
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹7,453 Cr
- P/E
- 62.0x
- P/B
- 14.4x
- EV / EBITDA
- 52.5x
- EV / Sales
- 14.2x
- P/S
- 14.2x
- Earnings yield
- 1.6%
- 52-week high
- ₹648.50
- 52-week low
- ₹349.75
Profitability
- Operating margin
- 26.0%
- Net margin
- 13.5%
- EBITDA margin
- 27.1%
- ROE
- 13.8%
- ROCE
- 24.6%
- ROA
- 11.5%
- Dividend payout
- 134.0%
- Tax rate
- 28.0%
- Other income, % of PBT
- 6.1%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹633 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 20.8%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 5.5%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹142 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 18.3%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 35.2%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -2.1%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹155 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 29.2%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹12.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 1.3%
Solvency and efficiency
- Current ratio
- 6.76
- Debt / Equity
- 0.08
- Debt / Assets
- 0.06
- Debt / EBITDA
- 0.27
- Interest coverage
- 27.20
- Financial leverage
- 1.21
- CFO / Net profit
- 2.18
- Cash / Market cap
- 2.3%
- Cash per share
- ₹10.63
- Asset turnover
- 0.85
- Fixed asset turnover
- 3.30
- Capital intensity
- 0.30
- Debtor days
- 28 days
- Inventory turnover
- 3.44
- Cash conversion cycle
- 51 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹15 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹445 Cr |
| Sales | Operating profit | ₹188 Cr |
| Operating profit | Interest | ₹3 Cr |
| Operating profit | Depreciation | ₹47 Cr |
| Operating profit | Profit before tax | ₹138 Cr |
| Other income | Profit before tax | ₹13 Cr |
| Profit before tax | Tax and other | ₹55 Cr |
| Profit before tax | Net profit | ₹96 Cr |
Revenue and net profit
Revenue grew 20.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹474 Cr | ₹120 Cr |
| FY2022 | ₹562 Cr | ₹152 Cr |
| FY2023 | ₹486 Cr | ₹57 Cr |
| FY2024 | ₹524 Cr | ₹71 Cr |
| FY2025 | ₹633 Cr | ₹96 Cr |
Cash flows
FY2025: ₹191 Cr from operations, ₹136 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹111 Cr | ₹58 Cr |
| FY2022 | ₹106 Cr | ₹94 Cr |
| FY2023 | ₹120 Cr | ₹88 Cr |
| FY2024 | ₹155 Cr | ₹75 Cr |
| FY2025 | ₹191 Cr | ₹136 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹633 Cr+20.8%1Y
- Net profit
- ₹96 Cr+35.2%1Y
- Cash from operations
- ₹191 Cr
- Free cash flow
- ₹136 Cr+81.3%1Y
- Revenue CAGR, 5Y
- 5.5%
- EBITDA CAGR, 5Y
- 1.3%
- Net profit CAGR, 5Y
- -2.1%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹633 Cr | ₹188 Cr | — | ₹96 Cr | ₹191 Cr | ₹136 Cr | 17.9% | +20.8% | +35.2% |
Monthly returns
Month-by-month returns of THYROCARE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹676 Cr |
| Equity capital | ₹53 Cr |
| Reserves | ₹484 Cr |
| Borrowings | ₹23 Cr |
| Other liabilities | ₹116 Cr |
| Assets | ₹676 Cr |
| Fixed assets | ₹158 Cr |
| Capital work in progress | ₹14 Cr |
| Investments | ₹284 Cr |
| Other assets | ₹221 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
THYROCARE trades at 62.0x earnings against a peer median of 52.1x (a 19% premium).
Not shown (no positive earnings and no EV / Sales): Tejas Networks Limited.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Thyrocare Technologies LimitedTHYROCAREthis companyP/E ↑ premium | ₹7,453 Cr | 62.0x | 14.4x | 13.8% | 52.5x |
| C.E. Info Systems LimitedMAPMYINDIA | ₹8,564 Cr | 57.0x | 10.0x | 20.9% | 45.5x |
| MTAR Technologies LimitedMTARTECH | ₹8,101 Cr | 175.0x | 10.8x | 8.3% | 69.2x |
| RateGain Travel Technologies LimitedRATEGAIN | ₹7,819 Cr | 94.5x | 5.6x | 3.4% | 119.9x |
| VA Tech Wabag LimitedWABAG | ₹7,383 Cr | 25.1x | 3.9x | 15.8% | 18.1x |
| GARWARE HI-TECH FILMS LIMITEDGRWRHITECH | ₹6,982 Cr | 21.8x | 2.9x | 9.2% | 23.9x |
| Tejas Networks LimitedTEJASNET | ₹6,668 Cr | — | 2.0x | 2.6% | 21.5x |
| TANLA PLATFORMS LIMITEDTANLA | ₹6,599 Cr | 25.4x | 13.0x | 25.7% | 34.5x |
| Happiest Minds Technologies LimitedHAPPSTMNDS | ₹6,535 Cr | 31.9x | 4.2x | 16.7% | 16.6x |
| Peer median | — | 52.1x | 7.8x | 14.5% | 34.2x |
Year-to-date ROI
THYROCARE since 1 January, against earlier years.
Historical volatility
THYROCARE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 36.0% |
| FY2022 | 41.0% |
| FY2023 | 24.0% |
| FY2024 | 26.0% |
| FY2025 | 30.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹633 Cr |
| Costs | |
| Interest | ₹3 Cr |
| Expenses | ₹446 Cr |
| Operating profitOperating Profit | ₹188 Cr |
| Other income and charges | |
| Profit before tax | ₹151 Cr |
| Tax | |
| Net profitNet Profit | ₹96 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹676 Cr |
| Equity capitalEquity Capital | ₹53 Cr |
| Reserves | ₹484 Cr |
| Borrowings | ₹23 Cr |
| Other liabilitiesOther Liabilities | ₹116 Cr |
| AssetsTotal Assets | ₹676 Cr |
| Fixed assetsFixed Assets | ₹158 Cr |
| Capital work in progressCWIP | ₹14 Cr |
| Investments | ₹284 Cr |
| Other assetsOther Assets | ₹221 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹191 Cr |
| Investing cash flowCash from Investing Activity | -₹55 Cr |
| Financing cash flowCash from Financing Activity | -₹124 Cr |
| Change in cashNet Cash Flow | ₹12 Cr |
Learn while you research
Academy chapters picked for Thyrocare Technologies Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 62.0, learn when high multiples are justified.6 min read
- 04 Growth Investing21% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read